[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Pan B, Cheng T, Nan KJ, Qiu GQ, Sun XC: Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer. World J Gastroenterol; 2005 Jan 21;11(3):439-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer.
  • AIM: To investigate the therapeutic effects of Fuzheng Yiliu (strengthening the body resistance to inhibit tumor) decoction combined with chemotherapy on the patients with intermediate and late stage gastrointestinal cancer.
  • METHODS: Sixty patients were randomly divided into treatment group (chemotherapy combined with Fuzheng Yiliu decoction) and control group (chemotherapy alone).
  • Four indexes, including the tumor recent remission rate (RR), the change of main symptoms, the toxic and side effects caused by chemotherapy and the change of performance status, were observed in the patients.
  • Peripheral blood contents of CD3+, CD4+, CD8+ cells, CD4+/CD8+ and soluble interleukin-2 receptor (sIL-2R) were tested before and after treatment and the values were compared with those of healthy peoples.
  • RESULTS: The improving rate of main symptoms (69.6%) and performance status (56.7%) were significantly higher in the treatment group than in the control group (34.8%, 26.7%, P<0.05).
  • The occurrence rates of grade II toxic and side-effects on both bone marrow (13.3%) and digestive tract (30%) were lower in the treatment group compared to the control group (36.7%, 63.3%, P<0.05).
  • Before treatment, the proportion of CD3+, CD4+ and CD4+/CD8+ decreased and the proportion of CD8+ and sIL-2R raised markedly both in the control group and treatment group as compared to the healthy people.
  • After treatment, that increased of CD3+, CD4+, CD4+/CD8+ increased (62.25+/-10.01% vs 68.31+/-9.72%, 36.83+/-10.44% vs 42.6+/-9.62%, 1.24+/-0.65 vs 1.66+/-0.85, P<0.05) and the values of CD8+ and sIL-2R decreased obviously (33.06+/-7.69% vs 29.24+/-6.25%, 588.23+/-216.86 U/mL vs 475.87+/-211.36 U/mL, P<0.05) in the treatment group, whereas these values were opposite in the control group (64.22+/-6.91% vs 60.63+/-5.75%, 35.62+/-7.49% vs 31.53+/-5.53%, 32.95+/-8.28% vs 37.14+/-7.48%, 1.17+/-0.43 vs 0.94+/-0.43, 573.63+/-214.32 U/mL vs 692.17+/-221.33 U/mL, P<0.05).
  • CONCLUSION: Fuzheng Yiliu decoction can enhance therapeutic effects of chemotherapy on malignant gastrointestinal tumor, and also reduce the toxic and side effects on bone marrow and digestive tract, thereby improving the quality of life and cellular immunity in patients with malignant gastrointestinal tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology
  • [MeSH-minor] Adult. CD4-CD8 Ratio. Drug Synergism. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637764.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  • [Other-IDs] NLM/ PMC4205358
  •  go-up   go-down


2. Mao AW, Gao ZD, Xu JY, Yang RJ, Xiao XS, Jiang TH, Jiang WJ: Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion. World J Gastroenterol; 2001 Aug;7(4):587-92
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion.
  • AIM: To study the palliative treatment of malignant obstruction of digestive tract with placement of intraluminal stent combined with intra-arterial infusion of chemotherapeutic drugs.
  • METHODS: A total of 281 cases of digestive tract malignant obstruction were given per oral (esophagus, stomach, duodenum and jejunum), per anal (colon and rectum) and percutaneous transhepatic (biliary) installation of metallic stent.
  • Among them, 203 cases received drug infusion by cannulation of tumor supplying artery with Seldinger's technique.
  • Occurrence of restenotic obstruction was 8-43 weeks among those with intra-arterial drug infusion, which was later than 4-26 weeks in the group with only stent installation.
  • The average survival time of the former group was 43 (3-105) weeks, which was significantly longer than 13 (3-24) weeks of the latter group.
  • CONCLUSION: Intraluminal placement of stent combined with intra-arterial infusion chemotherapy is one of the effective palliative therapies for malignant obstruction of the digestive tract with symptomatic as well as etiological treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / surgery. Intestinal Obstruction / drug therapy. Intestinal Obstruction / surgery. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Palliative Care / methods. Quality of Life. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11819837.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC4688681
  •  go-up   go-down


3. Chen HS, Zhai F, Chu YF, Xu F, Xu AH, Jia LC: [Clinical study on treatment of patients with upper digestive tract malignant tumors of middle and late stage with Ginkgo biloba exocarp polysaccharides capsule preparation]. Zhong Xi Yi Jie He Xue Bao; 2003 Sep;1(3):189-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of patients with upper digestive tract malignant tumors of middle and late stage with Ginkgo biloba exocarp polysaccharides capsule preparation].
  • OBJECTIVE: To observe the clinical efficacy of Ginkgo biloba exocarp polysaccharides (GBEP) capsule preparation in treating upper digestive tract malignant tumors of middle and late stage.
  • METHODS: Eighty-six patients of the upper digestive tract malignant tumors were treated with GBEP capsule preparation taken orally.
  • The clinical symptoms and the qualities of life of the patients with single GBEP and combined with operation, radiotherapy or intervention chemotherapy were observed.
  • The tumor size was measured by electronic gastroscope before and after treatment with single GBEP.
  • Objective response rate (RR) of the tumor was calculated.
  • Karnofsky scoring of the patients markedly increased after treatment.
  • CONCLUSION: GBEP capsule preparation has some definite therapeutic effects on upper digestive tract malignant tumors of middle and late stage.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Ginkgo biloba. Plant Preparations / therapeutic use. Stomach Neoplasms / drug therapy. Upper Gastrointestinal Tract / pathology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Capsules. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Phytotherapy. Polysaccharides / administration & dosage. Polysaccharides / therapeutic use. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15339558.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Capsules; 0 / Plant Preparations; 0 / Polysaccharides
  •  go-up   go-down


Advertisement
4. Haugland HK, Jebsen NL, Mannelqvist M, Skar R, Eide J, Øvrebø K, Horn A, Jensen DK, Monge OR, Lilleng PK: [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate]. Tidsskr Nor Laegeforen; 2005 Apr 7;125(7):868-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
  • [Transliterated title] Behandling med imatinibmesylat av pasienter med gastrointestinal stromal tumor.
  • BACKGROUND: Gastrointestinal stromal tumour (GIST) is the most frequent mesenchymal tumour type of the digestive tract.
  • Between 30 and 40% of patients have high-risk, malignant GIST with poor prognosis after surgery.
  • We report our experience with imatinib mesylate in the treatment of GIST.
  • Eight patients had metastatic disease, one patient received adjuvant treatment.
  • The patients were evaluated according to standard protocols for clinical performance, effect of treatment, and adverse effects.
  • Tumour tissue was analysed for mutational status in KIT and PDGFRA.
  • The single patient receiving adjuvant treatment had no sign of recurrence.
  • INTERPRETATION: The results demonstrate that imatinib mesylate is an effective drug that can stabilise and reduce disease in patients with advanced GIST.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Gastrointestinal Stromal Tumors / drug therapy. Intestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815732.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


5. Ishihara S, Honda Y, Asato T, Nonaka M, Nakagawa S, Hirashima K, Hayashi N, Baba H, Iyama K: Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy. Pathol Res Pract; 2010 Jul 15;206(7):514-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy.
  • Neoplasms derived from interdigitating dendritic cell are extremely rare.
  • The ileal tumor, measuring 2cm, was detected and resected with regional lymphadenectomy.
  • At that time, a pathologic diagnosis of malignant peripheral nerve sheath tumor was made.
  • The patient, who was not treated with chemotherapy, showed no signs of recurrence.
  • Oval to spindle-shaped atypical cells, which resembled ileal tumor cells, infiltrated into the lymph node and duodenum.
  • Based on the histologic and immunohistochemical analysis, the histopathologic diagnosis of IDCS was confirmed.
  • To our knowledge, five cases of IDCS arising in the intestinal tract have been reported to date, and only one case, treated with both surgery and chemotherapy, led to remission.
  • This is the first case that has a comparatively favorable prognosis without chemotherapy after surgery.
  • [MeSH-major] Dendritic Cell Sarcoma, Interdigitating / pathology. Duodenal Neoplasms / pathology. Ileal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Diagnostic Errors. Digestive System Surgical Procedures. Humans. Immunohistochemistry. Male. Middle Aged. Nerve Sheath Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399026.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Clippe C, Ligneau B, Trillet-Lenoir V: [Role of gemcitabine in the treatment of other malignant tumors]. Bull Cancer; 2002 Aug;89 Spec No:S120-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of gemcitabine in the treatment of other malignant tumors].
  • [Transliterated title] Place de la gemcitabine dans le traitement des autres tumeurs malignes.
  • The therapeutic interest of gemcitabine both as a single drug and in combination is now well known and applied in various malignant diseases.
  • However, it would be worth being further explored in two tumor models for which its efficacy has been suspected and which have been somehow "abandoned" by modern oncology after the demonstration of their high sensitivity to platinum derivatives, namely epidermoid tumours of the upper aero-digestive tract and uterine cervix.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Cisplatin / administration & dosage. Clinical Trials as Topic. Combined Modality Therapy. Female. Gastrointestinal Diseases / chemically induced. Gastrointestinal Neoplasms / drug therapy. Hematologic Diseases / chemically induced. Humans. Lung Neoplasms / drug therapy. Melanoma / drug therapy. Organoplatinum Compounds / administration & dosage. Salvage Therapy. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12449042.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 9
  •  go-up   go-down


7. Rossi CR, Mocellin S, Mencarelli R, Foletto M, Pilati P, Nitti D, Lise M: Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer; 2003 Nov 1;107(2):171-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract.
  • These tumors span a wide clinical spectrum from benign to malignant and have long been recognized for their nearly absolute resistance to chemotherapy and radiation treatment.
  • We reviewed the worldwide experience on GIST diagnosis, prognosis and treatment and describe our own series.
  • PubMed was searched for references using the terms gastrointestinal stromal tumor, GIST and gastrointestinal sarcoma.
  • Recent reports were given emphasis because GIST is a novel clinical entity and older published work on gastrointestinal sarcomas might be contaminated with other histologic tumor types.
  • At present, surgery is the standard treatment for primary resectable GIST.
  • To increase the activity of conventional chemotherapeutic agents, locoregional therapies are being implemented in the clinical setting.
  • A major breakthrough is the development of a new class of anticancer agents targeting tumor-specific molecular abnormalities.
  • Preliminary results on administration of imatinib mesylate, a signal transduction inhibitor, are particularly encouraging, showing potent activity of this drug against metastatic GIST.
  • [MeSH-major] Gastrointestinal Neoplasms. Stromal Cells / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12949790.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


8. Terada T: Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute. Int J Clin Exp Pathol; 2009;3(2):162-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the digestive organs: a histopathologic study of 31 cases in a single Japanese institute.
  • The author herein reports histopathologic features of 31 surgical cases of gastrointestinal stromal tumor (GIST) of the digestive organs.
  • Endoscopy and imaging modalities including US, CT and MRI were useful to detect the tumors in all cases, and biopsies confirmed the GIST diagnosis in 21 cases.
  • Grossly, 23 cases were submucosal tumors, 6 serosa-side tumors, 1 solid tumor in the liver, and 1 rectal polyp.
  • Histologically, 28 cases were of spindle cell type and 3 of epithelioid type.
  • According to mitotic counts and tumor size, the malignant risk was very low in 4 cases, low in 14 cases, intermediate in 9 cases, and high in 4 cases.
  • The chemotherapy was imatinib mesylate in 6 cases, and none in 25 cases.
  • [MeSH-major] Academies and Institutes. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Tract / pathology
  • [MeSH-minor] Actins / metabolism. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Codon. Colonic Neoplasms / pathology. Female. Humans. Immunohistochemistry. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Japan. Liver Neoplasms / pathology. Male. Middle Aged. Point Mutation. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Sequence Deletion. Stomach Neoplasms / pathology. Tumor Burden. Vimentin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7256-9 [19084944.001]
  • [Cites] Med Oncol. 2009;26(2):233-7 [18777214.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1606-8 [14632569.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):29-34 [19047911.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • (PMID = 20126584.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Codon; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC2809996
  • [Keywords] NOTNLM ; GIST / KIT / PDGFRA / clinicopathology / desmin / genetics / immunohisology
  •  go-up   go-down


9. Wada I, Shimizu N, Seto Y: [Treatment of neuroendocrine tumors of the digestive tract]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1606-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of neuroendocrine tumors of the digestive tract].
  • Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors.
  • European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification.
  • The only curative therapy is the complete resection of the tumor.
  • Combination chemotherapy, such as Etoposide+Cisplatin/Carboplatin, is useful in treating unresected neuroendocrine carcinomas.
  • Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression.
  • Development of new effective drug is expected for the treatment of neuroendocrine tumors of the digestive tract.
  • [MeSH-major] Antinematodal Agents / therapeutic use. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838017.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents
  •  go-up   go-down


10. Bairy KL, Sanath S, Jagetia GC, Somayaji SN, Vidyasagar MS, Baliga MS: Evaluation of intraperitoneal vincristine in malignant peritoneal effusion. Indian J Physiol Pharmacol; 2003 Jul;47(3):270-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intraperitoneal vincristine in malignant peritoneal effusion.
  • The tumor bearing animals were administered with 0.5 mg/kg body weight (b.wt) of freshly prepared vincristine sulphate intraperitoneally on day 6 after tumor transplantation followed by drug administration once daily 5 days a week consecutively.
  • The observations regarding the survival, alteration in the volume of peritoneal fluid, increase in life span and pathological changes in the liver, kidney, gastrointestinal tract and bone tissues were made.
  • The vincristine sulphate treatment reduced the malignant cell population significantly and there were no significant changes in the histological picture of liver, kidney, bone, except the intestine, where atropy of villi demonstrating nests and cords of uniform small round cells were observed.
  • Our experimental data suggests that intraperitoneal administration of vincristine is beneficial in malignant peritoneal effusion.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Ascitic Fluid / drug therapy. Ascitic Fluid / etiology. Carcinoma, Ehrlich Tumor / complications. Vincristine / therapeutic use
  • [MeSH-minor] Animals. Cell Survival / drug effects. Digestive System / pathology. Female. Gastrointestinal Transit / drug effects. Injections, Intraperitoneal. Kidney / pathology. Liver / pathology. Mice. Rats. Rats, Wistar. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723312.001).
  • [ISSN] 0019-5499
  • [Journal-full-title] Indian journal of physiology and pharmacology
  • [ISO-abbreviation] Indian J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


11. Maksimovic S: Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience. Med Arh; 2010;64(2):116-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience.
  • After total gastrectomy it is necessary to reconstruct the upper part of the digestive tract.
  • The double tract (DT) method is the optimal reconstruction procedure aftertotal gastrectomy for patients with gastric cancer.
  • Tumor diffused in the sections of stomach in 37 cases: cardia and body in 14 cases, body and antrum in 16 cases, and in only body of stomach in 7 cases.
  • In the pathological examination, the tumors of 34 patients were diagnosed as adenocarcinoma, 2 as malignant lymphoma, and i as leiomyosarcoma.
  • CONCLUSIONS: The benefits of this method are (1) a simple procedure;.
  • [MeSH-major] Digestive System Surgical Procedures. Gastrectomy / rehabilitation. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514781.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


12. Ryan P, Nguyen VH, Gholoum S, Carpineta L, Abish S, Ahmed NN, Laberge JM, Riddell RH: Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol; 2009 Mar;33(3):475-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract.
  • PEComa of the gastrointestinal tract, composed of perivascular epithelioid cells with myomelanocytic differentiation, is rare with previous literature limited to 16 case reports.
  • We report PEComa with lymph node involvement occurring in the rectum of a 15-year-old girl, treated by surgical resection and adjuvant chemotherapy.
  • We review the differential diagnosis of intestinal PEComa, which includes malignant melanoma, epithelioid gastrointestinal stromal tumors, clear cell sarcoma of soft parts, alveolar soft part sarcoma, leiomyosarcoma with HMB45 expression, and paraganglioma.
  • We discuss the determination of pathologic features indicative of malignancy in PEComa, which is complicated in the gastrointestinal tract due to the small number of cases, variability of pathologic features reported, and inconsistent reporting of outcome.
  • All 4 tumors reporting early recurrence or progression were greater than 5 cm in size and had areas of coagulative tumor necrosis.
  • We propose that a minimum dataset for gastrointestinal PEComa should include these features along with mitotic count, infiltrative border, and tumor stage analogous to that used in colorectal carcinoma.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092636.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Sleijfer S, Seynaeve C, Wiemer E, Verweij J: Practical aspects of managing gastrointestinal stromal tumors. Clin Colorectal Cancer; 2006 Nov;6 Suppl 1:S18-23
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GISTs) are rare tumors of the digestive tract.
  • Gastrointestinal stromal tumors are one of the first solid tumor types in which specific factors responsible for malignant behavior have been elucidated and for which drugs specifically targeting these factors form the mainstay of treatment in advanced-stage disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101064.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 32
  •  go-up   go-down


14. Tulchinsky H, Keidar A, Strul H, Goldman G, Klausner JM, Rabau M: Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Arch Surg; 2005 Feb;140(2):159-63; discussion 164
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve patients had 14 desmoid tumors: 7 were treated surgically and 7 medically (these patients received celecoxib and tamoxifen citrate therapy).
  • Of the 41 patients who underwent upper gastrointestinal tract endoscopy, 11 developed duodenal and/or ampullary adenomas.
  • Two patients died--one of a huge mesenteric desmoid tumor and the other of an aggressive mesenteric malignant fibrous histiocytoma.
  • Early detection of desmoid tumors, duodenal, pouch, and rectal cuff adenomas by periodic computed tomography, gastroduodenoscopy, and pouchoscopy, respectively, may allow control by medical therapy, endoscopy, or limited surgical procedures.
  • In most patients control of desmoid tumors was achieved using a combination of celecoxib and tamoxifen citrate therapy.
  • [MeSH-minor] Adolescent. Adult. Celecoxib. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiography. Comorbidity. Drug Therapy, Combination. Endoscopy, Digestive System. Female. Fibromatosis, Aggressive / drug therapy. Fibromatosis, Aggressive / radiography. Fibromatosis, Aggressive / surgery. Humans. Male. Middle Aged. Pyrazoles / therapeutic use. Retrospective Studies. Sulfonamides / therapeutic use. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723997.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 094ZI81Y45 / Tamoxifen; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


15. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • Endocrine tumors (ET) of the digestive tract (formerly called neuroendocrine tumors) are rare.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • Ileal ET's, even if small, are malignant, frequently multiple, and complicated in 30-50% of cases by bowel obstruction, mesenteric invasion, or bleeding.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


16. Doi T: [GIST]. Gan To Kagaku Ryoho; 2008 May;35(5):737-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumor (GIST) is the most frequent mesenchymal neoplasm of the gastrointestinal tract.
  • Mutation results in constitutive activation of the Kit receptor tyrosine kinase, which induces malignant cell proliferation.
  • Although STI571 was first applied to GIST, it has already revolutionized the treatment of patients with metastases.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487909.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / sunitinib; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 8
  •  go-up   go-down


17. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, Berry DP, Dennison AR: Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci; 2008 Dec;53(12):3213-7
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Carbohydrate antigen 19.9 (CA19.9), a tumor marker for malignancies of the hepatobiliary tract and pancreas, has frequently been shown to be deranged in a number of non-malignant conditions that are associated with jaundice.
  • All patients were thoroughly investigated and followed up until the diagnosis of malignancy could be safely excluded.
  • CONCLUSION: CA19.9 level is significantly influenced by serum bilirubin and elevated levels have been observed in patients with non-malignant HPB conditions.
  • Adjusting CA19.9 according to bilirubin levels is likely to improve the specificity of this antigen in the differential diagnosis of benign and malignant HPB diseases and its reliability in the monitoring of disease response to chemotherapy.
  • [MeSH-minor] Biomarkers / blood. Cholecystitis / blood. Cholecystitis / diagnosis. Diagnosis, Differential. Gallstones / blood. Gallstones / diagnosis. Humans. Hyperbilirubinemia / blood. Regression Analysis. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]
  • [Cites] J Clin Lab Anal. 2007;21(2):103-6 [17385665.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1941-6 [10406263.001]
  • [Cites] J Clin Gastroenterol. 2007 Jan;41(1):115-7 [17198074.001]
  • [Cites] JOP. 2007 May 09;8(3):335-43 [17495364.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Feb;19(2):167-9 [17273004.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] JOP. 2007 Mar 10;8(2):191-7 [17356242.001]
  • [Cites] Dig Dis Sci. 1989 Oct;34(10):1640-2 [2791822.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):142-7 [17262731.001]
  • [Cites] Endoscopy. 2007 Aug;39(8):720-4 [17661248.001]
  • [Cites] Int J Urol. 2005 Feb;12(2):214-6 [15733120.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1013-6 [10737382.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):29271-8 [7961897.001]
  • [Cites] Am J Clin Pathol. 2007 Mar;127(3):436-40 [17276945.001]
  • [Cites] Eur J Clin Invest. 1992 Dec;22(12):800-4 [1478251.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1125-7 [17342388.001]
  • [Cites] World J Gastroenterol. 2007 Jan 14;13(2):289-93 [17226911.001]
  • [Cites] J Surg Res. 2007 Jun 1;140(1):31-5 [17418869.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1108:359-71 [17893999.001]
  • [Cites] World J Gastroenterol. 2007 Oct 28;13(40):5357-9 [17879406.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):195-9 [15999098.001]
  • (PMID = 18465243.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


18. Lee DK: Drug-eluting stent in malignant biliary obstruction. J Hepatobiliary Pancreat Surg; 2009;16(5):628-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-eluting stent in malignant biliary obstruction.
  • INTRODUCTION: In unresectable malignant bile duct obstruction, endoscopic stent insertion is the treatment of choice.
  • However, the current stent allows only mechanical palliation of the obstruction, and has no anti-tumor effect.
  • Currently, in the vascular field, the drug-eluting stent (DES) is very highly favored.
  • MATERIAL AND METHODS: The requirements for a DES in a non-vascular tract, such as the bile duct, are far different from those of a DES to be used in the vascular tract.
  • The non-vascular DES must suppress tumor proliferation as well as mucosal hyperplasia.
  • We do not have much experience with DES in the bile duct.
  • Nonetheless, we are continuously testing many anti-tumor agents in animal and human studies.
  • CONCLUSION: We expect and hope DES will work effectively for tumor cells in diverse ways and, more importantly, will prolong stent patency and the patients' survival periods.
  • But considerable investigation and a clinical study of DES will be required to achieve these goals.
  • [MeSH-major] Bile Duct Neoplasms / therapy. Cholestasis / pathology. Cholestasis / therapy. Drug-Eluting Stents
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Catheterization / instrumentation. Endoscopy, Digestive System / methods. Female. Humans. Male. Prognosis. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554255.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 24
  •  go-up   go-down


19. Testroote M, Hoornweg M, Rhemrev S: Rectal GIST presenting as a submucosal calculus. Dig Dis Sci; 2007 Apr;52(4):1047-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report presents an incidental finding of a rectal GIST (gastrointestinal stromal tumor) presenting as a submucosal calculus, not previously reported.
  • X-ray photos, computerized tomography (CT)-scan and a magnetic resonance imaging (MRI) scan clearly showed a calculus.
  • Analysis showed it was a rectal GIST, a rare mesenchymal tumor of the gastrointestinal tract, which expressed CD117 (or c-kit, a marker of kit-receptor tyrosine kinase) and CD34.
  • In general, GISTs are rare mesenchymal tumors of the gastrointestinal tract (nerve tissue, smooth muscle).
  • A set of histologic criteria stratifies GIST for risk of malignant behavior such as mitotic activity and tumor size, cellular pleomorphism, developmental stage of the cell and quantity of cytoplasma [7,13].
  • Tumors with a high mitotic activity and size above 5 cm are considered malignant.
  • Recent pharmacological advances such as tyrosine kinase inhibitors have determined c-kit (i.e., CD117) as the most important marker, amongst others.
  • C-kit positive tumors respond extremely well to chemotherapy with Imatinib (Glivec, Gleevec) [10-12].
  • [MeSH-major] Calculi / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Rectal Diseases / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Calcinosis / complications. Calcinosis / diagnosis. Calcinosis / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Ureteral Calculi / complications. Ureteral Calculi / diagnosis. Ureteral Calculi / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol. 2003;38(2):186-9 [12640535.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2051-5 [14606351.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):373-7 [15086741.001]
  • [Cites] Clin Radiol. 2004 Jun;59(6):487-98 [15145718.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] J Gastroenterol. 2000;35(10):779-83 [11063223.001]
  • [Cites] Eur Radiol. 2001;11(2):216-9 [11218017.001]
  • [Cites] Am Surg. 2001 Feb;67(2):135-7 [11243536.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Mar;13(3):283-6 [11293450.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • (PMID = 17268837.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1914226
  •  go-up   go-down


20. Harries K, Nunn T, Shah V, Richards D, Manson JM: First reported case of esophageal paraganglioma. A review of the literature of gastrointestinal tract paraganglioma including gangliocytic paraganglioma. Dis Esophagus; 2004;17(2):191-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First reported case of esophageal paraganglioma. A review of the literature of gastrointestinal tract paraganglioma including gangliocytic paraganglioma.
  • Macroscopically the tumor may be pedunculated, sessile or ulcerated and have been described up to 10 cm in size.
  • The majority of reported tumors have been benign, only 7% malignant at presentation and all with lymph node metastases.
  • One case developed bone metastases 3 years after excision and another recurred locally.
  • There has been no benefit seen from radiotherapy or chemotherapy to date and it is recommended that all of these tumors are widely excised together with a lymph node resection if possible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15230739.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


21. Brassens S, Chevalier JM, Leblainvaux M: [A strange case of phlebitis]. Ann Cardiol Angeiol (Paris); 2003 Dec;52(6):375-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This sarcoma developed from the smooth muscle of a leg vessel, probably a vein.
  • Leiomyosarcoma is a malignant mesenchymal tumor of specialized connective tissue, with a strong potential for local proliferation and metastatic spread.
  • It usually involves the uterine muscle or the wall of the digestive tract, as well as the large vessels of the abdomen and thorax, the prostate very seldom, and only exceptionally a peripheral vein as in this case.
  • The diagnosis suggested by imaging techniques (in particular MRI) is first and foremost immunohistochemical.
  • The treatment is surgical when possible, associated with radiotherapy and chemotherapy as appropriate.
  • The prognosis is especially poor when the diagnosis is made at the metastatic stage.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Popliteal Vein / pathology. Thrombophlebitis / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Fatal Outcome. Humans. Knee / blood supply. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14752921.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, Barbosa MM, Gonçalves FB Jr: Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg; 2003 Jul;129(7):794-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nasopharyngeal cancer (NPC) is a distinct form of cancer of the upper respiratory or digestive tract in which the epidemiologic features, origin, histopathologic types, treatment, and prognosis are different from those associated with other malignant neoplasms of this anatomical area.
  • Recent publications have demonstrated the advantage of aggressive multimodality treatment for advanced NPC.
  • OBJECTIVES: To evaluate the results of standardized treatment of NPC during 11 years and to identify pertinent factors for clinical outcome.
  • METHODS: Between January 1, 1989, and December 31, 2000, 173 patients with newly diagnosed NPC were treated at Instituto Nacional de Cancer.
  • Documented data of the initial presenting symptoms, head and neck examination, radiotherapy protocols, chemotherapy regimens, and surgical technique were analyzed.
  • To determine important prognostic factors, we correlated survival rates with age, clinical stage, tumor extent, histopathological type, and therapeutic approach.
  • Gross extension of the primary tumor involving the facial bones and skull base was observed in 39.3% and 20.8%, respectively.
  • Just under 75% of patients were treated with radiotherapy (median dose, 6600 cGy), and 25.4% underwent concomitant chemoradiotherapy with adjuvant chemotherapy (cisplatin plus 5-fluorouracil) (median dose, 6800 cGy).
  • The disease-specific survival for the radiotherapy group was 22.5%, compared with 61.4% for the chemoradiotherapy plus adjuvant chemotherapy group (P =.004).
  • Factors associated with adverse outcomes were age older than 40 years at treatment (P =.001), advanced TNM stage (P =.002), skull base invasion (P =.004), and facial bone invasion (P<.001).
  • CONCLUSIONS: Compared with radiotherapy alone, concomitant chemoradiotherapy with adjuvant chemotherapy improved the treatment outcome of patients with NPC treated in our institution.
  • [MeSH-major] Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brachytherapy. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874084.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Goker H, Haznedaroglu IC, Chao NJ: Acute graft-vs-host disease: pathobiology and management. Exp Hematol; 2001 Mar;29(3):259-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It causes a wide variety of host tissue injuries.
  • Total-body irradiation (TBI) or high-dose chemotherapy regimens cause extensive damage and activation in host tissues, which release inflammatory cytokines and enhance recipient major histocompatibility complex (MHC) antigens.
  • The skin, gastrointestinal tract, and liver are major target organs of acute GVHD.
  • Combination drug prophylaxis in GVHD is essential in all patients undergoing allogeneic HSCT.
  • Steroids have remained the standard for the treatment of acute GVHD.
  • Several clinical trials have evaluated monoclonal antibodies or receptor antagonist therapy for steroid-resistant acute GVHD, with different successes in a variety of settings.
  • Future experimental and clinical studies on GVHD will shed further light on the better understanding of the disease pathobiology and generate the tools to treat malignant disorders with allogeneic HSCT with specific graft-vs-tumor effects devoid of GVHD.
  • [MeSH-minor] Acute Disease. Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antigen Presentation. Antineoplastic Agents / adverse effects. Bone Marrow / drug effects. Bone Marrow / immunology. Bone Marrow / pathology. Bone Marrow / radiation effects. Digestive System / drug effects. Digestive System / immunology. Digestive System / pathology. Digestive System / radiation effects. Dogs. Drug Design. Drug Therapy, Combination. Forecasting. HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Liver / drug effects. Liver / immunology. Liver / pathology. Liver / radiation effects. Lymphocyte Depletion. Lymphokines / physiology. Mice. Models, Biological. Premedication. Radiation Chimera. Radiation Injuries / immunology. Radiation Injuries / pathology. Randomized Controlled Trials as Topic. Receptors, Interleukin-2 / antagonists & inhibitors. Risk Factors. Severity of Illness Index. Skin / drug effects. Skin / immunology. Skin / pathology. Skin / radiation effects. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / transplantation. Transplantation Conditioning / adverse effects. Transplantation, Homologous / adverse effects. Transplantation, Homologous / immunology. Whole-Body Irradiation / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Exp Hematol 2001 May;29(5):653
  • (PMID = 11274753.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / Lymphokines; 0 / Receptors, Interleukin-2
  • [Number-of-references] 215
  •  go-up   go-down






Advertisement